Drug profile

The FDA adverse-event record for Canine Influenza Virus H3N2;Canine Influenza Virus H3N8

348 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Influenza Virus H3N2;Canine Influenza Virus H3N8. See the species affected, top reactions, and outcomes below.

348
adverse-event reports
10.3%
death-coded share
Dog
most-reported species
115
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
348
Total Reports
36
Deaths Reported
10.3%
Death Rate

Active Ingredients

Canine Influenza Virus H3N2;Canine Influenza Virus H3N8

Administration Routes

SubcutaneousUnknownOralNasal

Species Affected

Dog 348

Most Affected Breeds

Retriever - Labrador 32
Chihuahua 23
Retriever - Golden 21
Terrier - Bull - American Pit 17
Dachshund (unspecified) 16
Shepherd Dog - Australian 15
Terrier (unspecified) 15
Crossbred Canine/dog 14
Terrier - Yorkshire 13
Shih Tzu 13

Most Reported Reactions

Vomiting 115
Lethargy (see also Central nervous system depression in Neurological) 78
Facial swelling (see also Skin) 52
Diarrhoea 50
Anaphylaxis 46
Emesis (multiple) 31
Fever 30
Pale mucous membrane 29
Anorexia 26
Hives (see also Skin) 24
Not eating 21
Death by euthanasia 19

Outcome Breakdown

Ongoing
161 (46.3%)
Recovered/Normal
118 (33.9%)
Outcome Unknown
33 (9.5%)
Euthanized
19 (5.5%)
Died
17 (4.9%)

Canine Influenza Virus H3N2;Canine Influenza Virus H3N8 Adverse Event Insights

348 reports name Canine Influenza Virus H3N2;Canine Influenza Virus H3N8; 36 recorded a death outcome (10.3% of reported events, not a population-level mortality rate). Active ingredient: Canine Influenza Virus H3N2;Canine Influenza Virus H3N8. Administration routes: Subcutaneous, Unknown, Oral, Nasal.

By species: Dog (348 reports). By breed: Retriever - Labrador (32), Chihuahua (23), Retriever - Golden (21).

Leading clinical signs: Vomiting (115), Lethargy (see also Central nervous system depression in Neurological) (78), Facial swelling (see also Skin) (52), Diarrhoea (50). Outcome, 348 coded reports: Ongoing leads at 46.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.